MATUCCI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.749
EU - Europa 2.432
AS - Asia 786
SA - Sud America 26
OC - Oceania 23
AF - Africa 15
Totale 6.031
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.742
PL - Polonia 795
RU - Federazione Russa 795
IT - Italia 354
HK - Hong Kong 270
SG - Singapore 258
IE - Irlanda 165
SE - Svezia 141
CN - Cina 99
JO - Giordania 47
GB - Regno Unito 46
IN - India 35
FI - Finlandia 32
ID - Indonesia 31
VN - Vietnam 26
CH - Svizzera 25
AU - Australia 23
BR - Brasile 23
DE - Germania 20
BE - Belgio 14
FR - Francia 12
NL - Olanda 11
CI - Costa d'Avorio 8
UA - Ucraina 6
CA - Canada 5
ES - Italia 4
CZ - Repubblica Ceca 3
MA - Marocco 3
RO - Romania 3
AE - Emirati Arabi Uniti 2
BD - Bangladesh 2
EG - Egitto 2
KR - Corea 2
PH - Filippine 2
ZA - Sudafrica 2
AM - Armenia 1
AR - Argentina 1
AZ - Azerbaigian 1
BG - Bulgaria 1
CO - Colombia 1
CR - Costa Rica 1
GR - Grecia 1
HU - Ungheria 1
IQ - Iraq 1
IR - Iran 1
JM - Giamaica 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
MN - Mongolia 1
PK - Pakistan 1
TH - Thailandia 1
TR - Turchia 1
UY - Uruguay 1
Totale 6.031
Salva come PNG Salva come JPEG
Città #
Warsaw 794
Santa Clara 779
Fairfield 278
Hong Kong 233
Chandler 178
Dublin 165
Ashburn 158
Singapore 157
Woodbridge 107
Seattle 106
Wilmington 106
Houston 105
Cambridge 103
Ann Arbor 93
Florence 78
Altamura 63
Lawrence 63
Moscow 51
Princeton 39
Buffalo 31
Shanghai 31
Beijing 29
Jakarta 29
Mumbai 25
Boston 24
Dong Ket 24
Melbourne 23
New York 21
Kent 20
San Diego 20
Medford 19
Bern 18
Luni 18
Milan 18
Helsinki 16
Los Angeles 16
Brussels 14
Boardman 11
London 10
Rome 10
Abidjan 8
Norwalk 8
Liverpool 7
Livorno 7
Phoenix 7
Naples 6
Redwood City 6
Andover 5
Frankfurt am Main 5
Jacksonville 5
Lappeenranta 5
Castelliri 4
Chicago 4
Paris 4
Redmond 4
Toronto 4
Amman 3
Busto Arsizio 3
Calenzano 3
Campi Bisenzio 3
Caulonia 3
Genoa 3
Hillsboro 3
Morden 3
Peschiera 3
Siena 3
Torre del Greco 3
Washington 3
Yubileyny 3
Zurich 3
Acton 2
Bengaluru 2
Bologna 2
Canosa di Puglia 2
Craiova 2
Dhaka 2
Dubai 2
Falls Church 2
Johannesburg 2
Lambeth 2
Latina 2
Laurel 2
Leawood 2
Madrid 2
Milzano 2
Monopoli 2
Munich 2
Nanchang 2
Nerviano 2
Nola 2
Palermo 2
Parma 2
Portsmouth 2
Prague 2
Pune 2
Romainville 2
Salerno 2
Sant'Agata Bolognese 2
Seoul 2
Sommacampagna 2
Totale 4.274
Salva come PNG Salva come JPEG
Nome #
Hapten-Specific TH17 Cells in the Peripheral Blood of β-Lactam-Induced AGEP. 279
Immunoglobulin replacement therapy for yellow nail syndrome 265
The in vitro amplification of β-lactam-specific memory t cells improves the diagnostic performance of IGE detection and lymphocyte transformation test 206
Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies 184
Concomitant Bilastine and Montelukast as Additive Therapy for Seasonal Allergic Rhinoconjunctivits and Mild-to-Moderate Asthma. The SKY Study 183
Efficacy and safety of mepolizumab (Anti-Interleukin-5) treatment in Gleich's syndrome 170
High serum β-lactams specific/total IgE ratio is associated with immediate reactions to β-lactams antibiotics 168
Tocilizumab in Giant Cell Arteritis: A Real-Life Retrospective Study 166
Biweekly hizentra® in primary immunodeficiency: A multicenter, observational cohort study (IBIS) 164
Malattia di Anderson-Fabry 156
Skin testing and infliximab-specific antibodies detection as a combined strategy for preventing infusion reaction. 155
Autoimmune hepatitis in a patient affected by neuromyelitis optica: A new association. 146
Assays and strategies for immunogenicity assessment of biological agents. 145
Assessment of the risk of polyomavirus JC reactivation in patients with immune-mediated diseases during long-term treatment with infliximab 140
Miescher's cheilitis: Surgical management and long term outcome of an extremely severe case. 137
Corrigendum to "Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia" [Int. Immunopharmacol. 44 (2017) 38-42] 134
The Italian Registry for Primary Immunodeficiencies (Italian Primary Immunodeficiency Network; IPINet): Twenty Years of Experience (1999–2019) 133
Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes 129
Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency in Routine Clinical Practice: The VISPO Prospective Multicenter Study 128
Omalizumab dampens type 2 inflammation in a group of long-term treated asthma patients and detaches IgE from FcεRI 127
Manifestations of Antidrug Antibodies Response: Hypersensitivity and Infusion Reactions. 121
Subcutaneous Immunoglobulin Twenty Percent Every Two Weeks in Pediatric Patients with Primary Immunodeficiencies: Subcohort Analysis of the IBIS Study 120
High proportion of inflammatory CD62Llow eosinophils in blood and nasal polyps of severe asthma patients 118
Drug-Specific Th2 Cells and IgE Antibodies in a Patient with Anaphylaxis to Rituximab 118
Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia. 117
The percentage of patients achieving complete remission of urticaria increases with repeated courses of treatment 114
Seasonal Allergic Rhinitis Symptoms in Relation to COVID-19 108
COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey 107
Low-dose mepolizumab effectiveness in patients suffering from eosinophilic granulomatosis with polyangiitis 106
Prompt Predicting of Early Clinical Deterioration of Moderate-to-Severe COVID-19 Patients: Usefulness of a Combined Score Using IL-6 in a Preliminary Study 105
Clinical outcome, incidence, and SARS-CoV-2 infection-fatality rates in Italian patients with inborn errors of immunity 98
Early experience of an infectious and tropical diseases unit during the coronavirus disease (COVID-19) pandemic, Florence, Italy, February to March 2020 91
Effectiveness of low-dose intravenous immunoglobulin therapy in minor primary antibody deficiencies: a two-year real-life experience 87
Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab. 86
Persistence of both reversible airway obstruction and higher blood eosinophils may predict lung function decline in severe asthma 86
Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice 81
The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer 80
Blood CD62Llow inflammatory eosinophils are related to the severity of asthma and reduced by mepolizumab 79
Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions 78
The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders 75
Long-term retention rate of mepolizumab treatment in severe asthma: a 36-months real-life experience 66
Anti-RuvBL1/2 Autoantibodies Detection in a Patient with Overlap Systemic Sclerosis and Polymyositis 66
Drug-specific Treg cells are induced during desensitization procedure for rituximab and tocilizumab in patients with anaphylaxis 65
Efficacy and safety of dupilumab in the treatment of CRSwNP in the real-life setting: a review of the literature 64
Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent 62
Primary antibody deficiencies represent an underestimated comorbidity in asthma patients: efficacy of immunoglobulin replacement therapy in asthma control 61
Effectiveness of tocilizumab in hospitalized moderate-to-severe COVID-19 patients: a real-life study 61
Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent 60
EGPA Phenotyping: Not Only ANCA, but Also Eosinophils 54
Baseline Eosinophil Count as a Potential Clinical Biomarker for Clinical Complexity in EGPA: A Real-Life Experience 47
Case Report: A child with NFKB1 haploinsufficiency explaining the linkage between immunodeficiency and short stature 46
Management of patients with chronic rhinosinusitis with nasal polyps (CRSwNP): Results from a survey among allergists and clinical immunologists of the North-west and Center Italy Inter-Regional Sections of SIAAIC and otorhinolaryngologists of National IAR 43
Managing Patients with Hypereosinophilic Syndrome: A Statement from the Italian Society of Allergy, Asthma, and Clinical Immunology (SIAAIC) 37
Asthma remission one, none and one-hundred thousand: the relevance of the patient’s view 30
Mechanisms of Action of Ig Preparations: Immunomodulatory and Anti-Inflammatory Effects 28
Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life 16
null 12
Totale 6.108
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.481
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.481
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020233 0 0 0 0 0 0 0 0 84 63 75 11
2020/2021637 52 60 6 87 41 69 42 38 74 91 34 43
2021/2022301 5 11 18 11 11 29 18 34 16 24 47 77
2022/2023862 65 186 49 43 51 140 110 48 94 15 32 29
2023/2024519 11 29 61 30 50 56 36 99 14 43 58 32
2024/20252.506 96 282 171 484 713 331 78 185 166 0 0 0
Totale 6.108